Numerous therapeutics have already been approved for CRC treatment including the EGFR inhibitors Cetuximab and panitumumab [6, 9–12], the VEGF-A inhibitors bevacizumab and aflibercept [4, 5, 13], and the VEGFR2 inhibitors regorafenib and ramucirumab [8, 14, 15]. The gene discussed is EGFR; the disease is colorectal carcinoma.